Back
Rate this talk
Your peers have not rated this talk yet.
4-minute watch | Talk 1 of 2

EU CAR T: Access and reimbursement to CAR T-cell therapy

Why is timely reimbursement of CAR T important for our patients?

Anuradha Rajapakse
SYMPOSIUM
EU CAR T

Anuradha Rajapakse
Kite, a Gilead Company

Anuradha Rajapakse of Kite, a Gilead company, discusses access to CAR T therapies and the importance of timely reimbursement

Read more

Talks in this series

Anuradha Rajapakse presents at EU CAR T (Why is timely reimbursement of CAR T important for our patients?
4-minute watch | Talk 1 of 2
EU CAR T: Access and reimbursement to CAR T-cell therapy
Why is timely reimbursement of CAR T important for our patients?
Anuradha Rajapakse presents at EU CAR T (Why is timely reimbursement of CAR T important for our patients?
4-minute watch
EU CAR T: Access and reimbursement to CAR T-cell therapy

Why is timely reimbursement of CAR T important for our patients?

How can we address reimbursement challenges for CAR T?
5-minute watch | Talk 2 of 2
How can we address reimbursement challenges for CAR T?
Adam Hutchings
How can we address reimbursement challenges for CAR T?
5-minute watch

How can we address reimbursement challenges for CAR T?

Adam Hutchings

Anuradha Rajapakse presents at EU CAR T (Why is timely reimbursement of CAR T important for our patients?
4-minute watch | Talk 1 of 2
EU CAR T: Access and reimbursement to CAR T-cell therapy
Why is timely reimbursement of CAR T important for our patients?
Anuradha Rajapakse presents at EU CAR T (Why is timely reimbursement of CAR T important for our patients?
4-minute watch
EU CAR T: Access and reimbursement to CAR T-cell therapy

Why is timely reimbursement of CAR T important for our patients?

How can we address reimbursement challenges for CAR T?
5-minute watch | Talk 2 of 2
How can we address reimbursement challenges for CAR T?
Adam Hutchings
How can we address reimbursement challenges for CAR T?
5-minute watch

How can we address reimbursement challenges for CAR T?

Adam Hutchings

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.